verified SJR 1,202 · Q1 • database Scopus / SJR & Web of Science indexed

United States · W.B. Saunders

workspace_premium Q1 — Hematology lock Subscription

Seminars in Oncology

Seminars in Oncology is a journal indexed in SJR in Hematology and Oncology with an H index of 149. It has an SJR impact factor of 1,202 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,202.

Seminars in Oncology focuses its scope in these topics and keywords: cancer, breast, bone, gemcitabinenovel, role, fungal, options, smoking, systems, combined, ...

ISSN: 0093-7754

Publisher: W.B. Saunders

Category: Hematology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,202 Q1

H-index 149

Acceptance rate pie_chart

22% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,202

H-index

149

Docs (year)

Docs 3y

117

Total refs

1191

Cites 3y

375

Citable 3y

113

Cites/Doc 2y

2.23

Ref/Doc

59.55

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Bisphosphonates in the prevention of bone metastases: Current evidence

Will our planet be able to cope with the cancer burden in the next decade?

Chemotherapy for the treatment of oligodendroglial tumors

Challenging the platinum combinations: Docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non[ndash ]small cell lung cancer

Cervical cancer in Latin America

Cardiac toxicity of trastuzumab (herceptin): Implications for the design of adjuvant trials

Cancer: A reality in the emerging world

Cancer-induced systemic myeloid dysfunction: Implications for treatment and a novel nanoparticle approach for its correction

Cancer in older persons: an international issue in an aging world

Cancer immunotherapy with natural killer cells

Bone metastases: Approaches to management

Bone marrow angiogenesis in patients with active multiple myeloma

SHOW MORE ARTICLES

Bladder cancer in Africa: Update

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer

Bisphosphonates in oncology: Breast cancer and beyond

Assessing Decisional Capacity in the Elderly

Approaches to preclinical screening of antiangiogenic agents

Anticancer therapy targeting the erbB family of receptor tyrosine kinases

Angiogenesis-dependent diseases

Angiogenesis in multiple myeloma

Analysis of skeletal-related events in breast cancer and response to therapy

Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer

Advances in the treatment of non[ndash ]small cell lung cancer: Molecular markers take the stage

Adjuvant bisphosphonate therapy: The future

FAQs

Seminars in Oncology has an SJR of 1,202 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Seminars in Oncology is 22%.

Seminars in Oncology

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Seminars in Oncology?

What is the APC / publication cost?

What is the acceptance rate?